First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations

Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John, Ligang Xing, Dariusz Kowalski, Regan M. Memmott, Ozan Yazici, Meili Sun, Catherine A. Shu, Elvire Pons-Tostivint, Yun Fan, Gonzalo Fernandez-Hinojal, Elaine Shum, Mengzhao Wang, Federica Bertolini, D. Ross Camidge, Chengzhi Zhou, Ludovic Doucet, Qunying Hong, Jian Fang, Dingzhi Huang, Bo Jin, Yan Yu, Lorenzo Antonuzzo, Denis Moro-Sibilot, Jaafar Bennouna, Gilberto de Castro, Li Zheng, John V. Heymach

Open source

DOI
10.1056/nejmoa2604461
Published
2026-08-20
Container
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2604461,
  title = {First-Line Sunvozertinib in NSCLC with
                    <i>EGFR</i>
                    Exon 20 Insertion Mutations},
  author = {Caicun Zhou and Laurent Greillier and Geoffrey Liu and Thomas John and Ligang Xing and Dariusz Kowalski and Regan M. Memmott and Ozan Yazici and Meili Sun and Catherine A. Shu and Elvire Pons-Tostivint and Yun Fan and Gonzalo Fernandez-Hinojal and Elaine Shum and Mengzhao Wang and Federica Bertolini and D. Ross Camidge and Chengzhi Zhou and Ludovic Doucet and Qunying Hong and Jian Fang and Dingzhi Huang and Bo Jin and Yan Yu and Lorenzo Antonuzzo and Denis Moro-Sibilot and Jaafar Bennouna and Gilberto de Castro and Li Zheng and John V. Heymach},
  year = {2026},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa2604461},
  url = {https://doi.org/10.1056/nejmoa2604461}
}

RIS

TY  - JOUR
TI  - First-Line Sunvozertinib in NSCLC with
                    <i>EGFR</i>
                    Exon 20 Insertion Mutations
AU  - Caicun Zhou
AU  - Laurent Greillier
AU  - Geoffrey Liu
AU  - Thomas John
AU  - Ligang Xing
AU  - Dariusz Kowalski
AU  - Regan M. Memmott
AU  - Ozan Yazici
AU  - Meili Sun
AU  - Catherine A. Shu
AU  - Elvire Pons-Tostivint
AU  - Yun Fan
AU  - Gonzalo Fernandez-Hinojal
AU  - Elaine Shum
AU  - Mengzhao Wang
AU  - Federica Bertolini
AU  - D. Ross Camidge
AU  - Chengzhi Zhou
AU  - Ludovic Doucet
AU  - Qunying Hong
AU  - Jian Fang
AU  - Dingzhi Huang
AU  - Bo Jin
AU  - Yan Yu
AU  - Lorenzo Antonuzzo
AU  - Denis Moro-Sibilot
AU  - Jaafar Bennouna
AU  - Gilberto de Castro
AU  - Li Zheng
AU  - John V. Heymach
PY  - 2026
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa2604461
UR  - https://doi.org/10.1056/nejmoa2604461
ER  - 

APA

Zhou, C., Greillier, L., Liu, G., John, T., Xing, L., Kowalski, D., Memmott, R. M., Yazici, O., Sun, M., Shu, C. A., Pons-Tostivint, E., Fan, Y., Fernandez-Hinojal, G., Shum, E., Wang, M., Bertolini, F., Camidge, D. R., Zhou, C., Doucet, L., Hong, Q., Fang, J., Huang, D., Jin, B., Yu, Y., Antonuzzo, L., Moro-Sibilot, D., Bennouna, J., Castro, G. D., Zheng, L., & Heymach, J. V. (2026). First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2604461

Source records